PM ImagesInvestment summary My recommendation for Paycom (NYSE:PAYC) is a buy rating. I believe there are plenty of opportunities for PAYC to capture and grow in the long term. In particular, PAYC’s BEIT product has an extremely strong value proposition that I believe has immense pricing power that management is not leveraging at the moment. The revised sales strategy for customer relationship representatives to see through the entire lifecycle of each sale should also improve customer satisfaction, lea ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces:- (a) the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the Company; and (b) the appointment of Dr Dan Eldar as the new Chairman. Dr Eldar has been a Non-executive Director of the Company since 2016. He has more than 30 years of experience as a senior executive, leading global o ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces:- (a) the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the Company; and (b) the appointment of Dr Dan Eldar as the new Chairman. Dr Eldar has been a Non-executive Director of the Company since 2016. He has more than 30 years of experience as a senior executive, leading global o ...

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association ("EHA") Hybrid Congress, taking place on June 13-16, 2024 in Madrid, ...

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association (“EHA”) Hybrid Congress, taking place on June 13-16, 2024 in Madrid, ...

— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED's surufatinib and anti-PD-1 activity with Hengrui's camrelizumab, promoting the immune response against tumor cells — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces the initiation of a Phase II/III tr ...

Core Viewpoint - HUTCHMED (China) Limited has appointed Dr. Renu Bhatia as an Independent Non-executive Director, effective May 13, 2024, to enhance the Board's expertise in healthcare and finance sectors [1][2][3]. Group 1: Appointment Details - Dr. Bhatia has over 25 years of experience in healthcare, finance, fintech, and regulatory sectors, and is expected to provide valuable insights to the Board [1][2]. - The initial term of Dr. Bhatia's appointment will end at the next annual general meeting, with a director's fee of US$76,000 and US$8,000 for her role in the Technical Committee [4]. - Dr. Bhatia holds 16,000 ordinary shares in HUTCHMED, representing approximately 0.002% of its issued share capital [5]. Group 2: Background and Experience - Dr. Bhatia is the chairman and co-founder of Opharmic Technology (HK) Ltd, focusing on ultrasound technology for drug delivery, and co-founder of Asia Fintech Angels [2][3]. - She has held significant positions in public service and has a strong background in finance, having started her career at Goldman Sachs and HSBC Asset Management [3]. - Dr. Bhatia holds a Doctor of Medicine from the University of London, an MBA from Yale University, and a Postgraduate Diploma in Therapeutics and Medicine from The University of Hong Kong [3]. Group 3: Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [6]. - The company employs approximately 5,000 personnel, with a core team of about 1,800 in oncology/immunology [6].

Investors might want to bet on HUTCHMED (HCM) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a chang ...

Shares of HUTCHMED (HCM) have gained 12.8% over the past four weeks to close the last trading session at $18.91, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $26.12 indicates a potential upside of 38.1%.The average comprises five short-term price targets ranging from a low of $17 to a high of $45, with a standard deviation of $11.60. While the lowest estimate indicates a decl ...

Core Viewpoint - Fruquintinib has received a positive opinion from the CHMP for the treatment of previously treated metastatic colorectal cancer in the EU, potentially making it the first novel targeted therapy for this indication in over a decade [1][2][3] Company Overview - HUTCHMED, in partnership with Takeda, is advancing the development and commercialization of fruquintinib, which has shown significant survival benefits in patients with metastatic colorectal cancer [3][10] - Takeda holds the exclusive worldwide license to develop and market fruquintinib outside of mainland China, Hong Kong, and Macau [2][8] Clinical Trial Insights - The positive CHMP opinion is based on the results from the FRESCO-2 Phase III clinical trial, which demonstrated statistically significant improvements in overall survival and progression-free survival for patients treated with fruquintinib [5][6][8] - FRESCO-2 trial included patients from multiple regions, including the U.S., Europe, Japan, and Australia, and met all primary and key secondary endpoints [5][6] Market Context - Colorectal cancer (CRC) is a significant health issue, being the third most prevalent cancer globally, with over 935,000 deaths in 2020 [4] - In Europe, CRC was the second most common cancer in 2020, with approximately 520,000 new cases and 245,000 deaths [4] Product Information - Fruquintinib is a selective oral inhibitor of VEGFR-1, -2, and -3, designed to inhibit tumor angiogenesis with a manageable safety profile [7][8] - The drug has been approved in the U.S. under the brand name FRUZAQLA, based on data from two large Phase III trials involving a total of 734 patients [8][9]